GSK-3β is recently suggested to be a modulator of retinoid signaling as it strongly inhibits RARα-dependent myeloid leukemia differentiation in response to all-trans retinoic acid treatment 16, 17. The gene discussed is RARA; the disease is myeloid leukemia.